‘Feluda’ Test Is More Accurate And A Potential Substitute For RT-PCR: Scientists

New Delhi: India’s CRISPR ‘Feluda’ COVID-19 test is more accurate than a rapid antigen test, scientists have said. It could become a cheaper, faster and simpler alternative to an RT-PCR diagnosis of the novel coronavirus.

The ‘Feluda’ test, termed after eminent writer and director Satyajit Ray’s famous detective character, is priced at Rs 500 and can deliver a result in 45 minutes. The test can also differentiate SARS-CoV-2 from other coronaviruses even though genetic variations between them are small.

The test — developed by New Delhi-based CSIR-Institute of Genomics and Integrative Biology (IGIB) and the Tata Group — is like a pregnancy strip test; it changes colour if the SARS-CoV-2 virus is detected.

Debojyoti Chakraborty, one of the developers of the test and a senior scientist at CSIR-IGIB, told PTI that the test has shown 96 per cent sensitivity and 98 per cent specificity for detecting the novel coronavirus.

“The CRISPR technology uses a highly specific CAS9 protein to find and bind to the target COVID signature. This is then coupled with paper-strip chemistry to elicit a visual readout on a paper strip,” he further said.

Virologist Upasana Ray remarked that the Feluda test is cheaper than RT-PCR, which costs Rs 1600 and above.

“Feluda is an alternative to the quantitative RT-PCR tests and is highly specific. It is capable of detecting low copy number nucleic acids (less viral RNA quantity) as well as single nucleotide variations,” Ray, a senior scientist at CSIR-IICB, Kolkata, was quoted as saying.

“This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable and reliable test in less than 100 days. The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use,” the statement released by the researchers said.


Get real time updates directly on you device, subscribe now.

Comments are closed.